January 3, 2018 / 9:19 PM / 20 days ago

BRIEF-Momenta And Mylan Announce Development Strategy For Proposed Biosimilar To Eylea

Jan 3 (Reuters) - Momenta Pharmaceuticals Inc:

* MOMENTA AND MYLAN ANNOUNCE DEVELOPMENT STRATEGY FOR M710, A PROPOSED BIOSIMILAR TO EYLEA® (AFLIBERCEPT)

* MYLAN NV - CO, MOMENTA PLAN TO INITIATE A PIVOTAL CLINICAL TRIAL FOR M710 IN PATIENTS IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below